Kazia Therapeutics (KZIA)

Beyond Inhibition

Reprogramming Cancer Control

Kazia Therapeutics is a clinical-stage oncology company focused on developing therapies for aggressive solid tumors. We are advancing a new paradigm in cancer treatment by leveraging precision pathway inhibition to reprogram cancer biology, restore anti-tumor immunity, and overcome treatment resistance.

Learn More About Us

Complementary Layers of Cancer Control

A Novel Tumor Microenvironment Epigenetic Strategy

We are advancing next-generation therapeutics that target multiple layers of cancer and immune control. Our multi-modal platforms targeting tumor dormancy are designed to overcome metastases, recurrence, and resistance in aggressive and immunotherapy-refractory cancers.

Paxalisib: Dual PI3K/mTOR Inhibitor

Paxalisib is a brain-penetrant, oral, once-daily small molecule that acts as a dual PI3K/mTOR inhibitor, targeting key pathways that drive tumor growth and survival. Beyond its core kinase inhibition, it also influences tumor epigenetic regulation, transcriptional state, and the immune microenvironment.

Learn More About Paxalisib

PD-L1 Protein Degrader Platform

The PD-L1 Protein Degrader Platform represents a first-in-class strategy to target unique tumor-specific nuclear PD-L1 post-translational forms not found in healthy cells. This novel target was identified through a reverse-translation liquid-biopsy profiling AI platform. Our lead asset, NDL2, is designed to selectively engage tumor-associated nuclear PD-L1 protein while sparing normal cellular PD-L1 and extending beyond the reach of traditional antibody-based approaches.

Learn More About PD-L1 Protein Degrader Platform

SETDB1 Inhibitor Platform

The SETDB1 Inhibitor Platform represents a first-in-class approach focused on disease-associated SETDB1 biology, an emerging driver of immune evasion, treatment resistance, and metastasis. Our lead asset, MSETC, is designed to selectively target pathogenic SETDB1 complexes while sparing normal cellular function, offering a novel strategy to reprogram cancer biology.

Learn More About SETDB1 Inhibitor Platform

A Pipeline Powering Precision Therapies

We are advancing a diversified portfolio of development candidates across multiple technologies. This positions us to deliver first- and best-in-class therapies across a range of oncology indications.

View Our Pipeline

Targeted Technology that Transforms Patient Outcomes

Our platform leverages precision pathway inhibition to reprogram the biological networks that drive immune evasion, therapeutic resistance, and metastatic progression, thus creating the potential for deeper, more durable responses than conventional pathway blockade alone.

Learn About Our Technology

Latest News

Aug 28, 2026 7:30 am EDT Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering

Aug 27, 2026 4:09 pm EDT Kazia Therapeutics Limited Announces Proposed Public Offering

Aug 27, 2026 4:01 pm EDT Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer

Jul 28, 2026 7:30 am EDT Kazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast Cancer

Jun 2, 2026 7:30 am EDT Kazia Therapeutics Appoints James Levine as Chief Financial Officer

May 26, 2026 7:30 am EDT Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer

Apr 15, 2026 8:00 am EDT Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform

Apr 13, 2026 5:05 pm EDT Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform

Jan 30, 2026 8:00 am EST Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

View All Press Releases